Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Terminated × Neurofibromatosis 2 × Clear all

Phase

Phase 2 3 Phase 3 1 Phase 2/3 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 72 Breast Neoplasms 68 Neoplasms 64 Prostatic Neoplasms 43 Lung Neoplasms 37 Neoplasm Metastasis 32 Leukemia, Myeloid, Acute 28 Colorectal Neoplasms 28 Ovarian Neoplasms 23 Multiple Myeloma 22 Head and Neck Neoplasms 22 Pain 21 Colonic Neoplasms 21 Carcinoma, Hepatocellular 21 Pancreatic Neoplasms 20 Lymphoma 18 Rectal Neoplasms 17 Lymphoma, Follicular 17 Leukemia 17 Urinary Bladder Neoplasms 16 Melanoma 16 Recurrence 15 Lymphoma, Non-Hodgkin 15 Lymphoma, Large B-Cell, Diffuse 14 Leukemia, Lymphocytic, Chronic, B-Cell 14 Stomach Neoplasms 12 Precursor Cell Lymphoblastic Leukemia-Lymphoma 12 Squamous Cell Carcinoma of Head and Neck 11 Myelodysplastic Syndromes 11 Leiomyoma 11

Interventions

brolucizumab 1 aflibercept 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03710564 2023-01-30

MERLIN

Novartis

Phase 3 Terminated

535 enrolled 14 charts

Macular Degeneration, Neurofibromatosis 2

Data powered by HemOnc (CC BY 4.0) Colophon ⚡